FTC Blasts Androgel Pay-For-Delay Ruling In 11th Circ.

Law360, Los Angeles (June 12, 2012, 4:04 PM ET) -- The Federal Trade Commission on Monday urged the Eleventh Circuit to reconsider its ruling that upheld the so-called pay-for-delay deals Solvay Pharmaceuticals Inc. inked to block generic versions of its blockbuster drug Androgel, saying the decision permitted weak patents to stifle competition.

The antitrust regulator petitioned the appeals court to review en banc its decision that rejected the FTC's appeal contending that Solvay's settlements in 2006 that resolved patent litigation with generic drugmakers should be viewed as unlawful restraints of trade.

The FTC argued that by...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required